Last reviewed · How we verify
Vancocin (vancomycin)
At a glance
| Generic name | vancomycin |
|---|---|
| Sponsor | ANI Pharmaceuticals |
| Target | Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Bacterial endocarditis
- Bacterial septicemia
- Clostridium difficile diarrhea
- Diphtheroid Prosthetic Heart Valve Endocarditis
- Infection due to Staphylococcus aureus
- Infection of bone
- Infectious disorder of joint
- Infective endocarditis
- Lower respiratory tract infection
- Neonatal Group B Streptococcal Septicemia
- Neonatal pneumonia
- Osteomyelitis due to Staphylococcus aureus
- Prosthetic Heart Valve Endocarditis
- Pseudomembranous enterocolitis
- Sepsis of the newborn
- Staphylococcal Prosthetic Heart Valve Endocarditis
- Staphylococcal endocarditis
- Staphylococcal enterocolitis
- Staphylococcal infectious disease
- Staphylococcal pneumonia
Common side effects
- Nephrotoxicity
- Hypokalemia
- Urinary tract infection
- Peripheral edema
- Insomnia
- Constipation
- Anemia
- Depression
- Vomiting
- Hypotension
- Nausea
- C. difficile colitis
Serious adverse events
- Nephrotoxicity
- Ototoxicity
- Neutropenia
- Anaphylaxis
- Stevens-Johnson syndrome
- Red Man Syndrome
- Toxic epidermal necrolysis
- Drug reaction with eosinophilia and systemic symptoms
- Acute generalized exanthematous pustulosis
- Linear IgA bullous dermatosis
Key clinical trials
- Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens (Phase 4)
- TheUseofLocalVancomycinPowdertoPreventPeriprostheticJointInfectioninPrimaryTotalHipandKneeArthroplasty.ARandomizedControlledTrial. (Phase 2)
- Phase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder. (Phase 1)
- Microbiome Effect of Omadacycline on Healthy Volunteers (Phase 1)
- A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous (Phase 3)
- A Phase II Randomized Trial to Evaluate the Impact of Fecal Microbiota Transplantation Using the Penn Microbiome Therapy Products on Recipient and Environmental Colonization With Multidrug-Resistant O (Phase 2)
- Exploring Vancomycin Disposition in Neonates: Paired Analysis of Vancomycin Concentrations Using Immunoassay and Liquid-chromatography-tandem Mass Spectrometry. Determination of Vancomycin Protein Bin (Phase 4)
- Powdered Intrawound Vancomycin in Open Fractures: a Randomized Controlled Trial (Phase 4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 11517609 | 2035-11-06 | Method of Use |
| 10188697 | 2035-11-06 | Formulation |
| 10039804 | 2035-11-06 | Formulation |
| 10849956 | 2035-11-06 | Formulation |
| 11000567 | 2035-11-06 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancocin CI brief — competitive landscape report
- Vancocin updates RSS · CI watch RSS
- ANI Pharmaceuticals portfolio CI